
Targeted nanoagents for the detection of cancers
Author(s) -
McCarthy Jason R.,
Bhaumik Jayeeta,
Karver Mark R.,
Sibel Erdem S.,
Weissleder Ralph
Publication year - 2010
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2010.08.003
Subject(s) - aptamer , the renaissance , cancer therapy , computational biology , nanotechnology , ligand (biochemistry) , cancer , nanomaterials , chemistry , small molecule , targeted therapy , cancer research , biology , materials science , microbiology and biotechnology , biochemistry , receptor , art , genetics , art history
Nanotechnology has enabled a renaissance in the diagnosis of cancers. This is due, in part to the ability to develop agents bearing multiple functionalities, including those utilized for targeting, imaging, and therapy, allowing for the tailoring of the properties of the nanomaterials. Whereas many nanomaterials exhibit localization to diseased tissues via intrinsic targeting, the addition of targeting ligands, such as antibodies, peptides, aptamers, and small molecules, facilitates far more sensitive cancer detection. As such, this review focuses upon some of the most poignant examples of the utility of affinity ligand targeted nanoagents in the detection of cancer.